NASDAQ:JAGX Jaguar Animal Health Q2 2026 Earnings Results & Report $0.42 0.00 (0.00%) Closing price 11/13/2026 04:00 PM EasternExtended Trading$0.40 -0.02 (-4.73%) As of 09:09 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Jaguar Animal Health beat analyst earnings expectations but missed on revenue in its Q2 2026 results, released August 19, 2026. The company reported EPS of -$15.70 versus the -$782.25 consensus estimate, while revenue of $1.23 million fell short of the $4.24 million estimate by $3.02 million. Research:ProfileEarnings HistoryForecast Earnings Announcement Details QuarterQ2 2026Report DateAugust 19, 2026TimeAfter Market ClosesConference Call7:00 AM ET Jaguar Animal Health EPS ResultsActual EPS-$15.70Consensus EPS -$782.25Beat/MissBeat by +$766.55One Year Ago EPSN/AJaguar Animal Health Revenue ResultsActual Revenue$1.23 millionExpected Revenue$4.24 millionBeat/MissMissed by -$3.02 millionYoY Revenue GrowthN/AUpcoming EarningsJaguar Animal Health's Q3 2026 earnings is estimated for Monday, November 16, 2026, based on past reporting schedules, with a conference call scheduled on Tuesday, November 17, 2026 at 8:30 AM ET. Check back for transcripts, audio, and key financial metrics as they become available.Conference Call ResourcesPress Release (8-K)Quarterly Report (10-Q)SEC FilingEarnings HistoryCompany ProfilePowered by Earnings DocumentsPress Release(8-K)Quarterly report(10-Q) Jaguar Animal Health Q2 2026 Earnings FAQ Did Jaguar Animal Health beat earnings estimates for Q2 2026? Jaguar Animal Health (NASDAQ:JAGX) reported earnings of -$15.70 per share for Q2 2026, beating the consensus estimate of -$782.25. The report was announced on Wednesday, August 19, 2026. What was Jaguar Animal Health's revenue for Q2 2026? Jaguar Animal Health reported revenue of $1.23 million for Q2 2026, against a consensus estimate of $4.24 million. When is Jaguar Animal Health's next earnings date? Jaguar Animal Health's next earnings date is estimated for Monday, November 16, 2026. MarketBeat tracks confirmed and estimated earnings dates for Jaguar Animal Health on the company's earnings history page. Jaguar Animal Health Earnings HeadlinesJaguar Health to Hold Investor Webcast November 17 Regarding Q3 2026 Financials & Corporate UpdatesNovember 13 at 12:26 PM | usatoday.comJaguar Animal Health (JAGX) Projected to Announce Quarterly Earnings on ThursdayNovember 5, 2026 | americanbankingnews.comEvery Starlink dish pays this stockThere's a chip inside every Tesla and Starlink dish that Elon doesn't own. He pays royalties to use it. Now he's filed to launch 1,000,000 AI satellites, a move Dylan believes could mean a 100X bigger royalty bill starting December 8th. This free pick names the public company collecting on every unit.November 16 at 1:00 AM | Behind the Markets (Ad)Napo Pharmaceuticals provides recap of panel discussionNovember 2, 2026 | tipranks.comCSO of Napo Pharmaceuticals, a Jaguar Health Family Company, and Clinical Investigators Evaluating Crofelemer Conduct Panel Discussion at Pediatric Gastroenterology Conference ...November 2, 2026 | theglobeandmail.comJaguar Health, Inc.(BOIN:) dropped from S&P TMI IndexNovember 1, 2026 | marketscreener.comMSee More Jaguar Animal Health Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Jaguar Animal Health? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Jaguar Animal Health and other key companies, straight to your email. Email Address About Jaguar Animal HealthJaguar Health, Inc., formerly Jaguar Animal Health (NASDAQ:JAGX), develops prescription medicines for gastrointestinal disorders in humans and animals. The company’s research has focused on plant-derived compounds, including crofelemer, which is derived from the Croton lechleri tree. Jaguar’s animal-health product Canalevia-CA1 received FDA conditional approval for the treatment of chemotherapy-induced diarrhea in dogs. The company also develops and commercializes crofelemer-based medicines for human gastrointestinal conditions. Jaguar expanded beyond its original animal-health focus through its 2017 merger with Napo Pharmaceuticals, a company developing plant-based medicines for human health. Napo became a Jaguar subsidiary, and the combined company adopted the Jaguar Health name.View Jaguar Animal Health ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles 3 Building-Materials Stocks Rallying While Homebuilders Struggle to Find BuyersMarketBeat Week in Review – 11/9 - 11/13Nu Holdings Earnings Show a Compounder Priced Like a Brazil BetCerebras Q3 Results: How Much More Proof Does Wall Street Need?Applied Materials Beats and Raises, But Investors Stay Unconvinced3 Power and Grid Stocks That Could Keep Growing Even if AI Spending SlowsYETI Beat on Earnings, But Its Sales Tell a Different Story Upcoming Earnings Walt Disney (11/17/2026)Home Depot (11/17/2026)NVIDIA (11/17/2026)Lowe's Companies (11/18/2026)TJX Companies (11/18/2026)Target (11/18/2026)Palo Alto Networks (11/18/2026)NetEase (11/19/2026)Alibaba Group (11/19/2026)PDD (11/19/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.